Are Peptides Safe? What the Evidence Says, Peptide by Peptide

It depends on which peptide, whether it has FDA approval, and where the vial came from. Among the 150 peptides and related compounds listed on this site, 35 have a current FDA approval, while 111 have no FDA-approved product. Their safety grades split like this: 30 are rated A, 60 B, 57 C, and 3 D.

Approved peptide drugs such as semaglutide have trial data on thousands of people. The most-searched research peptides often have only a few small human pilots, or none at all. So the honest answer is a safety grade and a source check, not a simple yes or no.

Approved peptide drugs. Prescription drugs like semaglutide and tirzepatide went through controlled trials before approval. Their side effects were counted in trials of 1,961 and 2,539 adults (PMID 33567185, PMID 35658024).

Compounded versions. FDA states that "compounded drugs are not FDA approved," so the agency does not review them for safety before sale. As of May 31, 2026, FDA had received 990 adverse-event reports for compounded semaglutide and over 730 for compounded tirzepatide. FDA says these numbers are likely underreported (FDA GLP-1 page).

Research-grade injectables. These vials often carry labels like "for research purposes" or "not for human consumption." Yet FDA reports that some GLP-1 vials labeled this way were sold for human use with dosing instructions. The agency calls those products "of unknown quality."

Topical cosmetic peptides. Several carry grade A on this site without any FDA approval. GHK-Cu is one: its published human data are small topical skin studies, and no human study has tested it as an injection.

Oral collagen products are dietary supplements, a separate topic this article leaves out. For dated FDA and compounding status on each tracked peptide, see the peptide regulatory tracker.

Every peptide profile on this site carries a safety grade from A to D. The editorial policy defines each one in plain words.

Grade A means "Strong safety profile. Backed by extensive human data or long-established use with minimal reported issues."

Grade B means "Good safety profile. Some human data exists, or extensive community use with few reported concerns."

Grade C means "Use caution. Limited human data. Safety profile based primarily on preclinical research and community reports."

Grade D means "Higher risk. Very limited data. Reported side effects or safety concerns from research or community use."

Grades follow the safety profile, not the FDA stamp. On this site, 7 grade A entries lack FDA approval, including GHK-Cu. Only 1 entry with current approval is rated grade C, cholecystokinin.

Grades from each peptide's profile on this site, FDA records as of Oct 10, 2026.

Grades from each peptide's profile on this site. Among entries with current approval, 60% are grade A (21 of 35), and 3% are grade C or D (1 of 35). Among the 111 without an approved product, 6% are grade A (7 of 111) and 53% are grade C or D (59 of 111).

The "Other FDA-approved listings" row holds a second entry for FDA-approved somatropin and three approved products that are not peptides: testosterone, L-carnitine, and orforglipron.

The 111 include 3 peptides whose FDA approval was later withdrawn: sermorelin, nesiritide, and enfuvirtide. Each time, the maker asked for the withdrawal because the product was no longer sold, not over a safety finding. Both lists, with dates, sit on the FDA-approved peptides page and the regulatory tracker.

The peptide evidence gap study checked the human research on each peptide on Oct 8, 2026. Of the 45 entries with no human study, 35 are rated grade C or D.

A 2015 review in Drug Discovery Today called peptide drugs "relatively safe and well tolerated" as a class (PMID 25450771). About 140 were in clinical trials when it was written. Each drug still has its own side-effect profile, and the big trials spell it out.

Semaglutide, grade A. In STEP 1, nausea and diarrhea were the most common side effects across 1,961 adults (PMID 33567185). The authors called them "typically transient and mild-to-moderate in severity." Gastrointestinal events made 4.5% stop the drug, versus 0.8% on placebo.

SELECT tracked 17,604 adults with cardiovascular disease for an average of 39.8 months (Lincoff 2023, NEJM). Side effects made 16.6% stop semaglutide for good, versus 8.2% on placebo. Over the same period, the main cardiovascular endpoint hit 6.5% of the semaglutide group and 8.0% of the placebo group.

Tirzepatide, grade A. SURMOUNT-1 included 2,539 adults with obesity (PMID 35658024). Side effects were mostly gastrointestinal and mild to moderate, mainly during dose escalation. They made 4.3% to 7.1% stop the drug across doses, versus 2.6% on placebo.

The drugmakers funded all three trials. Pooled analyses of many trials fill in the rarer side effects.

Signals across many trials. A 2022 meta-analysis covered 76 trials and 103,371 patients (PMID 35344001). It tied GLP-1 receptor agonists to more gallbladder or biliary disease, a relative risk of 1.37. In weight-loss trials, the relative risk rose to 2.29.

A separate 2025 Gastroenterology meta-analysis of 55 trials put numbers on the extra cases (PMID 40499738). It found 2 extra cholelithiasis cases and 4 extra GERD cases per 1,000 people treated.

Pancreatitis is still argued over. A 2025 pooled analysis found a relative risk of 1.44, which lost significance once trials were split by background medication (PMID 40988099). Overall it found no significant link to pancreatic cancer; one subgroup with background medication showed a signal the authors call likely minimal.

What users report. Members of r/Ozempic (~250k members) and r/semaglutide (~100k members) describe the same picture as the trials. Nausea during dose increases, constipation, and weight regain after stopping are common complaints.

Both drugs have strong community confidence on this site, and both profiles rate science and community as aligned. The semaglutide and tirzepatide profiles list every reported side effect.

These five draw the most US searches among peptides with no FDA-approved product. The ranking skips search terms the study flags as shared or ambiguous, such as "nad" and "vip". The search counts come from the peptide evidence gap study.

Grades from each peptide's profile on this site. Searches are the 12-month US average as of Oct 7, 2026.

Grades from each peptide's profile on this site. "Science" and "Community" reflect the confidence ratings each profile assigns to the published research and user reports. For all five, the evidence gap study sums up the fit the same way: "partly agrees with studies."

BPC-157, grade C. Studies: a 2025 systematic review screened 544 records and kept 36, of which 35 were preclinical and 1 clinical (PMID 40756949). Its finding on people was blunt: "No clinical safety data were found."

The human record is three uncontrolled pilots with 16, 12, and 2 patients (PMID 34324435, PMID 39325560, PMID 40131143). All three share the same first author.

A 120-person phase 2 trial began recruiting in 2026. FDA states that it has "no, or only limited, safety-related information" for the proposed routes (FDA bulk substances page).

User reports: across ~1,000+ r/Peptides threads, most users tolerate it well at standard doses. A meaningful minority report anxiety and panic, palpitations, anhedonia and emotional blunting, insomnia, and brain fog. Nausea shows up more with oral use, and people who feel nothing often blame purity.

Where they differ: the profile notes that mood effects "barely appear in preclinical literature: animal models cannot self-report mood effects." The profile rates its quality risk as high.

Glutathione, grade B. Studies: Japan approved it as an injection for drug poisoning, liver disease, and skin pigmentation. Wellness IV and oral uses are not approved anywhere.

A 2016 paper by Davids and colleagues is titled "Intravenous glutathione for skin lightening: Inadequate safety data" (PMID 27499402). A 2025 systematic review in the International Journal of Dermatology covers it as a skin-lightening agent. The one placebo-controlled IV trial it found saw 6 of 16 respond, or 37.5% (PMID 39444151).

User reports: across 50 to 150+ threads, skin brightening results look inconsistent and fade after stopping. Users also flag the higher risk of IV use, endotoxin contamination from non-pharmaceutical compounded products, injection-site reactions, and sulfite sensitivity.

Where they differ: recent reviews caution against the IV route, yet users keep using it. Quality risk is rated high.

GHK-Cu, grade A. Studies: the human data are small topical skin studies, such as a 2006 trial on laser-resurfaced skin (PMID 16847171). Pickart's reviews chart its effects on skin repair, mostly from lab and animal work (PMID 29986520). A 2024 lung-fibrosis study used a preclinical silicosis model (PMID 38879894).

No human study has tested GHK-Cu as an injection, and a 60-person phase 2 wound-gel trial is recruiting. Its pro-angiogenic activity raises a theoretical cancer concern that is still unresolved in humans.

User reports: users rate it one of the most tolerated anti-aging peptides. Across 100 to 200+ Reddit threads, they still flag "copper uglies" from topical overuse and injection-site burning, the top injectable complaint. Other issues include mcg versus mg mix-ups, a 1,000x error, and short stability after mixing.

Where they differ: the angiogenesis concern is described in the profile as "under-discussed in community protocols." Quality risk is rated medium.

MOTS-c, grade B. Studies: per the evidence gap study, "No study has given MOTS-c to people." Human studies only measure natural levels, and a 120-person phase 2 trial began recruiting in 2026.

Key papers include a 2015 Cell Metabolism study in mice (PMID 25738459) and a 2021 Nature Communications exercise study in mice (PMID 33473109). A 2025 mouse study of islet cells ran in Experimental and Molecular Medicine (PMID 40855115).

User reports: an estimated 500 to 2,000 active users report cost, injection-site irritation, and insomnia when dosed late in the day. MOTS-c is also WADA-prohibited.

Where they differ: users describe steady but subtle effects, while every efficacy result so far comes from rodents. Quality risk is rated medium.

TB-500, grade C. Studies: no published study has given the TB-500 fragment to people. FDA "has not identified any human exposure data" for it, and a phase 1/2 trial of 80 people began recruiting in 2026.

A 2010 trial gave full-length thymosin beta-4 by IV to 4 cohorts of 10 healthy volunteers, with no serious adverse events (PMID 20536472). That molecule isn't TB-500. Products sold as TB-500 contained the fragment Ac-LKKTETQ instead (PMID 22962027).

A 2023 lab analysis found TB-500 product contents "not systematically consistent" with their descriptions (PMID 36482504). User reports: about 500+ r/Peptides threads mention cost, contamination, mislabeling, endotoxin risk, and fatigue during the loading phase.

Where they differ: the profile is explicit: "Community confidence significantly exceeds what the fragment-specific evidence base strictly supports." Quality risk is rated high.

Purity on the label is not purity in the vial. A 2024 study ordered semaglutide from illegal online pharmacies without a prescription (Ashraf 2024, JMIR). The 3 vials received measured 7.7% to 14.37% purity against 99% stated on the label.

All 3 contained endotoxin, from 2.1645 to 8.9511 EU/mg, and had 28.56% to 38.69% more semaglutide than labeled. None of the 3 branded pens ordered ever arrived.

A Belgian lab tested falsified peptide drugs from illegal internet pharmacies (PMID 30029448). Purity ranged from 5% to 75% for cysteine-containing peptides.

One sample contained lead, and several reached up to ten times the ICH limit for injectable drugs. All arsenic detected was in the more toxic inorganic form.

Melanotan II vials sold online as 10 mg contained 4.32 to 8.84 mg in a 2015 test (PMID 24771717). Underdosing and overdosing both come from the same unchecked supply.

Compounded is not the same as approved. A study of FDA's adverse-event database found 707 reports for compounded products among 81,078 for GLP-1 drugs (PMID 40285721). Compared with branded products, reporting odds were 2.35 for hospitalization, 19.00 for contamination, and 48.92 for preparation errors. The same study found lower reporting odds for dosing errors (0.24) and administration errors (0.29) with compounded products.

These odds show reporting patterns, not rates, and don't prove cause. Separately, FDA's own page reports dosing errors with compounded semaglutide, some needing hospitalization.

Research-grade vials have the least oversight. FDA's bulk substances page flags immunogenicity risk and peptide-related impurities for BPC-157 and TB-500. For CJC-1295, it lists serious adverse events "including increased heart rate and systemic vasodilatory reaction."

All three now fall under "nominated but withdrawn" on that page, which is not an approval. The change log tracks each status change with its date.

Red flags on a vial. A label reading "for research purposes" or "not for human consumption" comes first. Other flags are a missing lot-specific certificate of analysis and a purity figure with no endotoxin or sterility test. Watch, too, for mg and mcg mixed up on the label.

Price says little about purity. A profile on this site puts it plainly: "a cheap or an expensive vial can be underdosed or contaminated." The guides on how to verify a peptide COA, peptide storage safety mistakes, and peptide dosing mistakes walk through each check.

A 2026 meta-analysis found a relative risk of 3.55 for injection-site reactions with GLP-1 drugs versus comparators (PMID 41395692). Skin reactions beyond the site were infrequent and not significantly increased.

Self-injection outside a clinic adds its own risks. Among 366 men using image- and performance-enhancing drugs, 42% had ever had redness, swelling, and tenderness at an injection site (PMID 24713416). And 6.8% had ever had an abscess or open wound.

The survey reported on these injectors as one group, not on peptide users, so treat it as a rough guide to self-injection risks.

Approved peptides can trigger antibodies too. In phase 3 trials, 51.1% of tirzepatide patients developed anti-drug antibodies, and neutralizing antibodies showed up in 1.9% and 2.1% (PMID 37700637). Efficacy held, but antibody-positive patients had more hypersensitivity and injection-site reactions; the authors are affiliated with the drugmaker.

For research peptides, FDA flags extra immunogenicity risk from aggregation and peptide-related impurities. A 2026 sports medicine review lists cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability as emerging risks (PMID 41880199). It adds that products are "often mislabeled or contaminated."

On this site, 149 of 150 profiles list pregnancy among contraindications. The exception is atosiban, a drug used for preterm labor that is given during pregnancy. Each profile's contraindications section is the place to check.

Tested athletes. A 2025 review notes BPC-157 is "banned in professional sports" (PMID 40756949). MOTS-c is WADA-prohibited, according to user reports on this site, and a 2026 review states that anti-doping detection continues to expand (PMID 41880199).

Gallbladder history and GLP-1 drugs. The risk of gallbladder or biliary disease was 2.29 times higher in weight-loss trials (PMID 35344001). That makes a gallbladder history worth raising with a prescriber.

SSRI or SNRI users and BPC-157. User reports on the BPC-157 profile tie anxiety and panic to higher doses or SSRI/SNRI use. This is a community report, not a trial finding.

Anyone who cannot verify the vial. FDA calls research-labeled GLP-1 products "of unknown quality." Only a lab test of that batch can tell a clean vial from a bad one.

Under 18. The site's terms require users to be 18 or older.

None of this is dosing or treatment advice. Talk to a clinician before starting any peptide, more so with a health condition or other medicines.

Each peptide profile shows the safety grade, regulatory status, and an evidence grade from the evidence gap study. Its science-versus-community panel rates confidence in each side and says whether the two align.

Data dates matter here. FDA records were retrieved Oct 10, 2026, the evidence check was conducted Oct 8, 2026, and search volumes are from Oct 7, 2026.

The FDA-approved peptides page lists every approval, and the evidence gap study rates the human research. The regulatory tracker follows compounding status, and the changes page logs each status change with dates.